Pyxis Oncology, Inc. Common Stock (PYXS) is a publicly traded Healthcare sector company. As of May 21, 2026, PYXS trades at $2.00 with a market cap of $127.98M and a P/E ratio of -1.47. PYXS moved +4.71% today. Year to date, PYXS is +65.29%; over the trailing twelve months it is +65.29%. Its 52-week range spans $0.83 to $5.55. Analyst consensus is strong buy with an average price target of $6.33. Rallies surfaces PYXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pyxis Oncology Completes Q1 Enrollment, Targets Mid-Year 5.4 mg/kg MICVO Data: Pyxis Oncology completed target enrollment for its MICVO Phase 1 monotherapy expansion in 2L+ R/M HNSCC Q1 2026 and expects mid-year data focusing on patients treated at or below a 5.4 mg/kg dose cap. The company projects cash runway into Q4 2026 and plans combination trial updates in H2 2026.
| Metric | Value |
|---|---|
| Price | $2.00 |
| Market Cap | $127.98M |
| P/E Ratio | -1.47 |
| EPS | $-1.31 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.55 |
| 52-Week Low | $0.83 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $13.86M |
| Net Income | $-81.73M |
| Gross Margin | 0.00% |
7 analysts cover PYXS: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.33.